Compare BioNano Genomics Inc (BNGO) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Credo Technology Group Holding Ltd — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Credo Technology Group Holding Ltd trades at $267.5 (market cap $46.19B). The key difference: Credo Technology Group Holding Ltd is far larger — about 3381.4× BioNano Genomics Inc's market cap, and Credo Technology Group Holding Ltd is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | CRDO | |
|---|---|---|
Market Cap | $13.66M | $46.19B |
Sector | Health | Technology |
52-Week High | $4.92 | $302.52 |
52-Week Low | $1.06 | $87.81 |
Enterprise Value | $16.26M | $44.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
CRDO trades at $275.98, up 15.02% in 24 hours, reflecting strong momentum. Technical indicators show a bullish trend with support at $243 and resistance at $250. The company reported robust earnings, beating estimates in Q3 2025, Q4 2025, and Q1 2026, with revenue surging 157% year-over-year in Q4 2025. Analyst consensus is strongly bullish, with 13 buy ratings and a price target of $285.42. Recent news highlights AI infrastructure demand driving growth, including contributions to the Open Compute Project.
Outlook is positive due to AI-driven demand and strong financial performance, but risks include high valuation multiples and customer concentration. The stock offers growth potential, yet investors should monitor execution risks and market volatility. Upside is supported by analyst targets, while downside protection exists near support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →
